As filed with the Securities and Exchange Commission
on April 2, 2024.
Registration No. 333-278006
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Amendment No. 1
to
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
MUSTANG BIO, INC.
(Exact name of registrant
as specified in its charter)
Delaware
(State or other jurisdiction of
incorporation or organization) |
|
2836
(Primary Standard Industrial
Classification Code Number) |
|
47-3828760
(I.R.S. Employer
Identification Number) |
377 Plantation Street
Worcester, Massachusetts 01605
(781) 652-4500
(Address, including zip code, and telephone number,
including area code, of registrant’s principal executive offices)
Manuel Litchman, M.D.
President and Chief Executive Officer
377 Plantation Street
Worcester, Massachusetts 01605
(781) 652-4500
(Name, address, including zip code, and telephone
number, including area code, of agent for service)
Copies to:
Rakesh Gopalan
Joseph Walsh
Troutman Pepper Hamilton Sanders LLP
301 S. College Street, 34th Floor
Charlotte, NC 28202
(704) 998-4050
Approximate
date of commencement of proposed sale to the public: As soon as practicable after the effective date of this Registration
Statement.
If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415
under the Securities Act of 1933, check the following box. x
If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act,
please check the following box and list the Securities Act registration statement number of the earlier effective registration statement
for the same offering. ¨
If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box
and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box
and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”
and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ¨ |
|
Accelerated filer ¨ |
Non-accelerated filer x |
|
Smaller reporting company x |
|
|
Emerging growth company ¨ |
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
The registrant hereby amends this Registration
Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which
specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the
Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to
said Section 8(a), may determine.
EXPLANATORY NOTE
Mustang Bio, Inc. is filing this Amendment
No. 1 (this “Amendment”) to its Registration Statement on Form S-1 (File No. 333-278006) (the ‘‘Registration
Statement”) solely to file Exhibits 1.4, 4.8, 4.9, 4.10 and 10.40. Accordingly, this Amendment consists only of the facing page,
this explanatory note, Item 16(a) of Part II of the Registration Statement, the exhibit index to the Registration Statement,
the signature page to the Registration Statement and the exhibits filed herewith. The prospectus, constituting Part I of the
Registration Statement, is unchanged and therefore has been omitted from this filing.
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 16. Exhibits and Financial
Statement Schedules.
The exhibits listed below are filed as part of this registration statement.
Exhibit No. |
Description |
Form |
File
Number |
Date |
Exhibit No. |
Filed
Herewith |
1.1 |
At
Market Issuance Sales Agreement, dated July 27, 2018, between the Company, B. Riley FBR, Inc., Cantor Fitzgerald &
Co., National Securities Corporation, and Oppenheimer & Co. Inc. |
8-K |
001-38191 |
July 27,
2018 |
1.1 |
|
1.2 |
Amendment
No. 1 to At Market Issuance Sales Agreement, dated July 20, 2020, between the Company, B. Riley FBR, Inc., Cantor
Fitzgerald & Co., National Securities Corporation and Oppenheimer & Co. Inc. |
8-K |
001-38191 |
July 24,
2020 |
1.2 |
|
1.3 |
Amendment
No. 2 to At Market Issuance Sales Agreement, dated December 31, 2020, between the Company, B. Riley Securities, Inc.,
Cantor Fitzgerald & Co., National Securities Corporation, Oppenheimer & Co. Inc. and H.C. Wainwright &
Co., LLC. (incorporated by reference to the Exhibit 1.1 of the Registrant’s Current Report on Form 8-K (file No. 001-38191)
filed with the SEC on December 31, 2020). |
8-K |
001-38191 |
December 31,
2020 |
1.1 |
|
1.4 |
Amendment
No. 3 to At Market Issuance Sales Agreement, dated April 14, 2023, between the Registrant B. Riley Securities, Inc.,
Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC |
8-K |
001-38191 |
April 20,
2023 |
1.1 |
|
2.1 |
Asset
Purchase Agreement, dated May 18, 2023, between the Company and uBriGene (Boston) Biosciences, Inc. # |
8-K |
001-38191 |
May 22,
2023 |
1.1 |
|
2.2 |
First
Amendment to Asset Purchase Agreement, dated June 29, 2023, between the Company and uBriGene (Boston) Biosciences, Inc. |
8-K |
001-38191 |
June 30,
2023 |
2.2 |
|
2.3 |
Second
Amendment to Asset Purchase Agreement, dated July28, 2023, between the Company and uBriGene (Boston) Biosciences, Inc. |
8-K |
001-38191 |
July 31,
2023 |
2.3 |
|
3.1 |
Amended
and Restated Certificate of Incorporation of Mustang Bio, Inc. (formerly Mustang Therapeutics, Inc.), dated July 26,
2016 |
10-12G |
000-5568 |
July 28,
2016 |
3.1 |
|
3.2 |
Certificate
of Amendment of the Amended and Restated Certificate of Incorporation of Mustang Bio, Inc., dated June 14, 2018 |
10-Q |
001-38191 |
August 13,
2018 |
3.1 |
|
3.3 |
Certificate
of Amendment of the Amended and Restated Certificate of Incorporation of Mustang Bio, Inc., dated September 30, 2019 |
8-K |
001-38191 |
September 30,
2019 |
3.1 |
|
3.4 |
Certificate
of Amendment of the Amended and Restated Certificate of Incorporation of Mustang Bio, Inc., dated December 4, 2020 |
8-K |
001-38191 |
December 4,
2020 |
3.1 |
|
3.5 |
Certificate
of Amendment of the Amended and Restated Certificate of Incorporation of Mustang Bio, Inc., dated June 17, 2021 |
8-K |
001-38191 |
June 22,
2021 |
3.1 |
|
3.6 |
Certificate
of Amendment of the Amended and Restated Certificate of Incorporation of Mustang Bio, Inc., dated July 5, 2022 |
8-K |
001-38191 |
July 7,
2022 |
3.1 |
|
3.7 |
Certificate
of Amendment of the Amended and Restated Certificate of Incorporation of Mustang Bio, Inc., dated April 3, 2023 |
8-K |
001-38191 |
April 3,
2023 |
3.1 |
|
3.8 |
Amended
and Restated Bylaws of Mustang Bio, Inc. |
8-K |
001-38191 |
April 3,
2023 |
3.2 |
|
4.1 |
Specimen
certificates evidencing shares of common stock, Class A common stock and Class A preferred stock |
10-12G |
000-5568 |
July 28,
2016 |
4.1 |
|
4.2 |
Form of
Warrant Agreement |
10-12G |
000-5568 |
July 28,
2016 |
4.2 |
|
4.3 |
Common
Stock Warrant issued by Mustang Bio, Inc. to NSC Biotech Venture Fund I, LLC, dated July 5, 2016 |
10-12G |
000-5568 |
July 28,
2016 |
10.5 |
|
4.4 |
Warrant
to Purchase Common Stock issued to Runway Growth Finance Corp., dated March 4, 2022 |
8-K |
001-3891 |
March 8,
2022 |
4.1 |
|
4.5 |
Form of
Pre-funded Warrant |
8-K |
001-38191 |
October 30,
2023 |
4.1 |
|
4.6 |
Form of
Warrant |
8-K |
001-38191 |
October 30,
2023 |
4.2 |
|
4.7 |
Form of
Wainwright Warrant |
8-K |
001-38191 |
October 30,
2023 |
4.3 |
|
4.8 |
Form of
Pre-Funded Warrant offered hereby |
|
|
|
|
X |
4.9 |
Form of
Warrant offered hereby |
|
|
|
|
X |
4.10 |
Form of
Placement Agent Warrant |
|
|
|
|
X |
5.1* |
Opinion
of Troutman Pepper Hamilton Sanders LLP |
|
|
|
|
|
10.1 |
Second
Amended and Restated Founders Agreement between Fortress Biotech, Inc. and Mustang Bio, Inc., dated July 26, 2016 |
10-12G |
000-5568 |
July 28,
2016 |
10.1 |
|
10.2 |
Management
Services Agreement between Fortress Biotech, Inc. and Mustang Bio, Inc., dated March 13, 2015 |
10-12G |
000-5568 |
July 28,
2016 |
10.2 |
|
10.3 |
Future
Advance Promissory Note to Fortress Biotech, Inc., dated May 5, 2016 |
10-12G |
000-5568 |
July 28,
2016 |
10.3 |
|
10.4 |
Promissory
Note to NSC Biotech Venture Fund I, LLC, dated July 5, 2016 |
10-12G |
000-5568 |
July 28,
2016 |
10.4 |
|
10.5 |
License
Agreement by and between Mustang Bio, Inc. and City of Hope, dated March 17, 2015 # |
10-12G |
000-5568 |
July 28,
2016 |
10.6 |
|
10.6 |
Sponsored
Research Agreement by and between Mustang Bio, Inc. and City of Hope, dated March 17, 2015 |
10-12G |
000-5568 |
July 28,
2016 |
10.7 |
|
10.7 |
Agreement
by and between Mustang Bio, Inc. and Chord Advisors, LLC, dated April 8, 2016 |
10-12G |
000-5568 |
July 28,
2016 |
10.10 |
|
10.8 |
Board
Advisory Services Agreement by and between Mustang Bio, Inc. and Caribe BioAdvisors, LLC |
10-K |
000-5568 |
March 31,
2017 |
10.11 |
|
10.9 |
Exclusive
License Agreement by and between Mustang Bio, Inc. and The Regents of the University of California, dated March 17, 2017
# |
10-Q |
000-5568 |
August 14,
2017 |
10.4 |
|
10.10 |
Exclusive
License Agreement (IV/ICV) by and between Mustang Bio, Inc. and City of Hope, dated February 17, 2017 # |
10-Q |
000-55668 |
August 14,
2017 |
10.5 |
|
10.11 |
Amended
and Restated Exclusive License Agreement (CD123) by and between Mustang Bio, Inc. and City of Hope, dated February 17,
2017 # |
10-K |
001-3891 |
March 31,
2017 |
10.14 |
|
10.12 |
Amended
and Restated Exclusive License Agreement (IL13Ra2) by and between Mustang Bio, Inc. and City of Hope, dated February 17,
2017 # |
10-K |
000-5568 |
March 31,
2017 |
10.15 |
|
10.13 |
Amended
and Restated Exclusive License Agreement (Spacer) by and between Mustang Bio, Inc. and City of Hope, dated February 17,
2017 # |
10-K |
000-5568 |
March 31,
2017 |
10.16 |
|
10.14 |
Employment
Agreement between Manuel Litchman and Mustang Bio, Inc., effective as of April 24, 2017 † |
8-K |
000-5568 |
April 24,
2017 |
10.1 |
|
10.15 |
License
Agreement (CSI) by and between Mustang Bio, Inc. and City of Hope, dated May 31, 2017 # |
10-Q/A |
001-38191 |
November 14,
2017 |
10.1 |
|
10.16 |
License
Agreement (PSCA) by and between Mustang Bio, Inc. and City of Hope, dated May 31, 2017 # |
10-Q/A |
001-38191 |
November 14,
2017 |
10.2 |
|
10.17 |
License
Agreement (HER2) by and between Mustang Bio, Inc. and City of Hope, dated May 31, 2017 # |
10-Q/A |
001-38191 |
November 14,
2017 |
10.3 |
|
10.18 |
Lease
Agreement by and between Mustang Bio, Inc. and WCS - 377 Plantation Street, Inc., dated October 27, 2017 |
10-Q |
001-3891 |
November 14,
2017 |
10.1 |
|
10.19 |
Sublease
Agreement by and between Mustang Bio, Inc., and The Paul Reverse Life Insurance Company, dated June 14, 2022 |
10-K |
001-3891 |
March 30,
2023 |
10.22 |
|
10.20 |
First
Amendment to Sublease Agreement by and between Mustang Bio, Inc. and The Paul Revere Life Insurance Company, dated October 25,
2022 |
10-K |
001-3891 |
March 30,
2023 |
10.23 |
|
10.21 |
Second
Amendment to Sublease, dated April 27, 2023, between the Company and The Paul Revere Life Insurance Company |
8-K |
001-38191 |
July 20,
2023 |
10.2 |
|
10.22 |
Third
Amendment to Sublease, dated June 15, 2023, between the Company and The Paul Revere Life Insurance Company |
8-K |
001-38191 |
July 20,
2023 |
10.3 |
|
10.23 |
Mustang
Bio, Inc. 2016 Incentive Plan † |
10-12G |
000-5568 |
July 28,
2016 |
10.8 |
|
10.24 |
Mustang
Bio, Inc. Non-Employee Directors Compensation Plan † |
10-12G |
000-5568 |
July 28,
2016 |
10.9 |
|
10.25 |
Amendment
to Mustang Bio, Inc. 2016 Incentive Plan |
DEF
14A |
001-3891 |
April 30,
2018 |
N/A |
|
10.26 |
Second
Amendment to the Mustang Bio, Inc. 2016 Equity Incentive Plan, dated June 17, 2021 † |
8-K |
001-3891 |
June 22,
2021 |
10.1 |
|
10.27 |
Third
Amendment to Mustang Bio, Inc. 2016 Equity Incentive Plan, dated June 21, 2022 † |
8-K |
001-3891 |
June 24,
2022 |
10.1 |
|
10.28 |
Form of
Option Agreement under the Mustang Bio, Inc. 2016 Incentive Plan |
10-K |
001-3891 |
March 11,
2024 |
10.28 |
|
10.29 |
Form of
Restricted Stock Unit Agreement under the Mustang Bio, Inc. 2016 Incentive Plan |
10-K |
001-3891 |
March 11,
2024 |
10.29 |
|
10.30 |
Form of
Director Stock Award Agreement under the Mustang Bio, Inc. Non-Employee Directors Compensation Plan |
10-K |
001-3891 |
March 11,
2024 |
10.30 |
|
10.31 |
Mustang
Bio, Inc. 2019 Employee Stock Purchase Plan † |
10-Q |
001-3891 |
August 9,
2019 |
10.1 |
|
10.32 |
Amendment
to the Mustang Bio, Inc. 2019 Employee Stock Purchase Plan, dated June 17, 2021 † |
8-K |
001-3891 |
June 22,
2021 |
10.2 |
|
10.33 |
Amendment
No. 2 to the Mustang Bio, Inc. 2019 Employee Stock Purchase Plan, dated June 21, 2023 † |
8-K |
001-3891 |
June 21,
2023 |
10.1 |
|
10.34 |
Loan
and Security Agreement by and between Mustang Bio, Inc., the Borrower, the Lenders, and Runway Growth Finance Corp. (as agent),
dated March 4, 2022 |
8-K |
001-38191 |
March 8,
2022 |
99.1 |
|
10.35 |
First
Amendment to Loan and Security Agreement by and between Mustang Bio, Inc., the Borrower, the Lenders and Runway Growth Finance
Corp. (as agent), dated December 7, 2022 |
8-K |
001-38191 |
December 13,
2022 |
10.1 |
|
10.36 |
Consulting
Agreement by and between Mustang Bio, Inc. and Danforth Advisors, LLC dated March 17, 2022 |
8-K |
001-38191 |
April 22,
2022 |
99.1 |
|
10.37 |
Manufacturing
Services Agreement, dated July 28, 2023, between the Company and uBriGene (Boston) Biosciences, Inc. |
8-K |
001-38191 |
July 31,
2023 |
10.1 |
|
10.38 |
Sub-Contracting
Manufacturing Services Agreement, dated July 28, 2023, between the Company and uBriGene (Boston) Biosciences, Inc. |
8-K |
001-38191 |
July 31,
2023 |
10.2 |
|
10.39 |
Form of
Securities Purchase Agreement, dated October 26, 2023, by and between the Company and the purchaser party thereto |
8-K |
001-38191 |
October 30,
2023 |
10.1 |
|
10.40 |
Form of
Securities Purchase Agreement |
|
|
|
|
X |
23.1^ |
Consent
of Independent Registered Public Accounting Firm, KPMG LLP |
|
|
|
|
|
23.2* |
Consent
of Troutman Pepper Hamilton Sanders LLP (included in Exhibit 5.1) |
|
|
|
|
|
24.1^ |
Power
of Attorney |
|
|
|
|
|
107^ |
Filing
Fee Table |
|
|
|
|
|
# Portions of this Exhibit have been omitted pursuant to Item
601(b)(1)(iv) of Regulation S-K.
† Management contract or compensatory plan.
* To be filed by amendment.
^ Previously filed.
SIGNATURES
Pursuant to the requirements of the Securities
Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Worcester, Commonwealth of Massachusetts, on this 2nd day of April, 2024.
|
MUSTANG BIO, INC. |
|
|
|
By: |
/s/
Manuel Litchman, M.D. |
|
Manuel Litchman, M.D. |
|
Chief Executive Officer and President |
Pursuant to the requirements of the Securities
Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
Signature |
|
Title |
|
Date |
/s/
Manuel Litchman |
|
President, Chief Executive
Officer and Director |
|
|
Manuel Litchman, M.D. |
|
(Principal Executive Officer) |
|
April 2,
2024 |
|
|
|
|
|
/s/
James Murphy |
|
Interim Chief Financial
Officer |
|
|
James Murphy |
|
(Principal Financial and
Accounting Officer) |
|
April 2,
2024 |
|
|
|
|
|
* |
|
Chairman of the Board
of Directors and Executive |
|
|
Michael S. Weiss |
|
Chairman |
|
April 2,
2024 |
|
|
|
|
|
* |
|
|
|
|
Adam Chill |
|
Director |
|
April 2,
2024 |
|
|
|
|
|
* |
|
|
|
|
Neil Herskowitz |
|
Director |
|
April 2,
2024 |
|
|
|
|
|
* |
|
|
|
|
Lindsay A. Rosenwald, M.D. |
|
Director |
|
April 2,
2024 |
|
|
|
|
|
* |
|
|
|
|
Michael Zelefsky, M.D. |
|
Director |
|
April 2,
2024 |
*By: |
|
/s/
James Murphy |
|
|
|
James Murphy |
|
|
|
Attorney-in-fact |
|